Estrella Immunopharma, Inc. current report, 03 April 2023

Full document

SEC Form 8-K Summary

Registrant: TradeUP Acquisition Corp. The provided metadata identifies Estrella Immunopharma, Inc., but the filing itself names TradeUP Acquisition Corp. as the registrant.

Business Context and Reporting Period

The Form 8-K was filed April 5, 2023, regarding an event occurring April 3, 2023. The company reported a Nasdaq listing deficiency under Listing Rule 5550(b)(2), the Market Value of Listed Securities standard.

Financial and Liquidity Information

The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating and financial metrics.

Material Changes Versus Prior Period

  • Nasdaq notified the company that its Market Value of Listed Securities remained below the required minimum of $35 million for 30 consecutive business days.
  • The notice is a deficiency notification only and did not immediately affect the listing or trading of the company’s securities on the Nasdaq Capital Market.

Outlook, Risks, and Contingencies

  • The company received 180 calendar days, until October 2, 2023, to regain compliance.
  • Compliance requires the company’s common-stock MVLS to be at least $35 million for a minimum of 10 consecutive business days during the compliance period.
  • If compliance is not regained by October 2, 2023, Nasdaq may issue a delisting notice. The company would have appeal rights under Nasdaq rules.
  • Management stated that it is monitoring MVLS and evaluating options to regain compliance, but provided no specific remediation plan.
  • The company cautioned that there can be no assurance it will regain or maintain compliance with Nasdaq listing standards.

Important Facts to Verify

  • Whether the company regained Nasdaq’s $35 million MVLS requirement by October 2, 2023, and maintained compliance thereafter.
  • Whether Nasdaq ultimately issued a delisting notice or accepted an appeal.
  • The source company identity, because the supplied metadata references Estrella Immunopharma, Inc., while the filing names TradeUP Acquisition Corp.
  • The company’s current Nasdaq listing status and any subsequent corporate transaction, name change, or ticker change.